Business
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies Veris
About this update from Lucid Diagnostics Inc.
[{"type":"text","content":"Lucid processed record test volume, saw rapid initial uptake in concierge medicine contracts, and secured first commercial insurance coverage policies \nVeris Health secured financing to resume advancement of implantable physiological monitor through FDA clearance and commercial launch \nPAVmed completed debt restructuring and Lucid deconsolidation to regain Nasdaq compliance and strengthen balance sheet\nConference call and webcast to be held today, March 25th, at 8:30 AM EDT\nNEW YORK, March 25, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (\"PAVmed\" or the \"Company\"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (\"Lucid\") and Veris Health Inc. (\"Veris\"), and reported financial results for the fourth quarter and full year ended December 31, 2024.\n\n \n \n \n \n \n \n\n \nConference Call and Webcast\nThe webcast will take place on Tuesday, March 25, 2025, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name \"PAVmed Business Update\" to join.\nFollowing the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.\nBusiness Update Highlights\n\"Following the critical steps taken to stabilize PAVmed's corporate structure and balance sheet, PAVmed is now in a very strong position to operate as it was designed—as a diversified commercial life sciences company with multiple independently-financed subsidiaries operating under a shared services model,\" said Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer. \"With Lucid and Veris both having sufficient capital to advance their commercial strategies, we expect PAVmed to directly benefit from their success. The performance of PAVmed's subsidiaries, particularly Lucid and its recent achievements with EsoGuard, serve as key drivers of PAVmed's long-term success and sustainability.\"\nHighlights...